From the Food and Drug Administration.
Nightingale
S L
SL
Office of Health Affairs, FDA, Rockville, MD 20857.
D016589:Astemizole / Q000009:adverse effects*; D000075202:Contraindications; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D016593:Terfenadine / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration; D016047:Zalcitabine / Q000008:administration & dosage*; D015215:Zidovudine / Q000008:administration & dosage*
D015215:Zidovudine; D016047:Zalcitabine; D016593:Terfenadine; D016589:Astemizole